Programs & Research

Our pipeline diversification offers opportunities to advance novel treatments across therapeutic areas and mechanisms of action

Abstract swirl background
Abstract swirl background

MM-120 | LSD D-tartrate

Lead Candidate with Evidence Across Multiple Therapeutic Areas

Extensive evidence of clinical benefit and mechanistic rationale in psychiatry, pain and substance use disorders

Psychiatry - Rapid & sustained benefit after acute dosing. 3x effect size compared to available affective disorder therapies. Safety & Pharmacology - 10,000+ patients treated in clinical trials. Well Characterized tolerability, pharmacokinetics and pharmacodynamics. Pain - Novel MOA that targets neurobiology of chronic pain. 2nd generation delivery opportunity to enhance access and scalability

Learn more about the study at our Clinical Trials page.

MM-110 | Zolunicant HCl

Novel Mechanism to Address a Critical Gap in OUD Treatment

Mechanism of action and target product profile complement standard-of-care and address a critical gap in available treatment landscape

MM-402 | R(-)-MDMA

Clinical Data Support Opportunity in ASD

Pilot clinical trial results of MDMA demonstrate acute and durable positive effects on social functioning in ASD population

Translational preclinical data suggest that R(-)-MDMA may have: Strong prosocial effects, Less stimulant activity compared to MDMA, Superior safety and tolerability profile, Potential to be administered in standard dosing regimen

1. Pitts 2018; Psychopharmacology; 235.

2. Curry 2018; Neuropharmacology; 128.

Translational preclinical data suggest that R(-)-MDMA may have:

  • Strong prosocial effects
  • Less stimulant activity compared to MDMA
  • Superior safety and tolerability profile
  • Potential to be administered in standard dosing regimen

Early R&D

External Collaborations Accelerate Discovery & Development

Leveraging key partnerships and collaborations to accelerate drug discovery and de-risk clinical development

MindShift: Discovery & Lead Optimization. nextage: Brain Targeted Liposomes (BTLS). Universitätsspital Bassel: Rapid DATA Generation & Clinical Concept Testing

Digital Medicine

External Collaborations Accelerate Discovery & Development

Leveraging key partnerships and collaborations to accelerate drug discovery and de-risk clinical development

Pre-Treatment
  • Patient education, engagement, preparation
  • Deep digital diagnosis
  • Support for treatment selection
During Treatment
  • In-session monitoring
  • Clinician decision support
  • Predictive models linking interventions and outcomes
Post-Treatment
  • Real world monitoring of trends
  • Engagement in health maintenance
  • AI models to inform psychotherapies